Ticker Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.

Aditya Birla Money Limited

Aditya Birla Money Limited

Medicamen Biotech Ltd

Symbol : MEDICAMEQ | BSE Code : 531146 | Sector : PHARMACEUTICALS - INDIAN - FORMULATIONS

241.194.24 (1.79%)
10-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

327.12
Today’s High / Low
247.99
237.00
52 Week High / Low
507.95
216.95
242.453.95 (1.66%)
10-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

328.83
Today’s High / Low
247.75
237.00
52 Week High / Low
506.05
220.00
241.194.24 (1.79%)
10-Apr-2026 | 12:00

Turnover (₹ Cr.)

58,122,981,007.50
Today’s High / Low
56,130
55,226.00
241.194.24 (1.79%)
10-Apr-2026 | 12:00

Turnover (₹ Cr.)

0.00
Today’s High / Low
0
0.00
OVERVIEW
  • Open
  • 239.99
  • Prev. Close
  • 236.95
  • High
  • 247.99
  • Low
  • 237.00
  • Market Cap (₹ Cr.)
  • 327.12
  • 52 Week High
  • 507.95
  • 52 Week Low
  • 216.95
  • Traded Volume (Lacs)
  • 38,975
  • Traded Value (Cr)
  • Dividend Yield
  • 0.39
  • Face Value
  • 10.00
  • EPS
  • 6.51
  • P/E
  • 37.24
  • Beta (1 year)
  • 1.02
OVERVIEW
  • Open
  • 241.55
  • Prev. Close
  • 238.50
  • High
  • 247.75
  • Low
  • 237.00
  • Market Cap (₹ Cr.)
  • 328.83
  • 52 Week High
  • 506.05
  • 52 Week Low
  • 220.00
  • Traded Volume (Lacs)
  • 1,618
  • Traded Value (Cr)
  • Dividend Yield
  • 0.39
  • Face Value
  • 10.00
  • EPS
  • 6.51
  • P/E
  • 37.24
  • Beta (1 year)
OVERVIEW
  • Open
  • 55,226.00
  • Prev. Close
  • 55,080.00
  • High
  • 56,130
  • Low
  • 55,226.00
  • Strike Price
  • 0.00
  • Open Interest(Nos.)
  • 2,084,700.00
  • OI Change %
  • -0.99
  • Volume(Lacs)
  • -0.99
  • Lot Size
  • 30.00
  • Average Price
  • 55,899.49
  • OI Difference
  • -20,850.00
  • Previous OI
  • 2,105,550.00
OVERVIEW
  • Open
  • 0.00
  • Prev. Close
  • 953.55
  • High
  • 0
  • Low
  • 0.00
  • Strike Price
  • 24,950.00
  • Open Interest(Nos.)
  • 2,730.00
  • OI Change %
  • 0.00
  • Volume(Lacs)
  • 0.00
  • Lot Size
  • 65.00
  • Average Price
  • 0.00
  • OI Difference
  • 0.00
  • Previous OI
  • 2,730.00
LAST 5 DAYS

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 54.33%

  • 12/04/2026 BSE
    3.95(1.66)
    Close Price: ₹ 242.45
    Volume: 1,618.00

    10-Apr-2026
  • 12/04/2026 BSE
    -1.95(-0.81)
    Close Price: ₹ 238.50
    Volume: 2,459.00

    09-Apr-2026
  • 12/04/2026 BSE
    13.60(6.00)
    Close Price: ₹ 240.45
    Volume: 2,249.00

    08-Apr-2026
  • 12/04/2026 BSE
    0.15(0.07)
    Close Price: ₹ 226.85
    Volume: 2,995.00

    07-Apr-2026
  • 12/04/2026 BSE
    -4.15(-1.80)
    Close Price: ₹ 226.70
    Volume: 1,629.00

    06-Apr-2026

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 54.33%

  • Stock Absolute
  • 6.95
  • -16.27
  • -51.14
  • -65.21
  • -52.30
  • Returns
  • 1W
  • 1M
  • 1Y
  • 3Y
  • 5Y
  • Sensex Absolute
  • 4.65
  • -0.84
  • 3.18
  • 29.58
  • 61.96
NEWS

Medicamen Biotech consolidated net profit declines 36.89% in the December 2025 quarter

14-Feb-2026

No Data Available

Net profit of Medicamen Biotech declined 36.89% to Rs 2.19 crore in the quarter ended December 2025 as against Rs 3.47 crore during the previous quarter ended December 2024. Sales rose 3.92% to Rs 46.91 crore in the quarter ended December 2025 as against Rs 45.14 crore during the previous quarter ended December 2024.

ParticularsQuarter Ended
Dec. 2025Dec. 2024% Var.
Sales46.9145.14 4
OPM %9.3414.86 -
PBDT3.946.09 -35
PBT2.113.88 -46
NP2.193.47 -37

14
Feb

Medicamen Biotech consolidated net profit declines 36.89% in the December 2025 quarter



05
Feb

Medicamen Biotech to convene board meeting



15
Nov

Medicamen Biotech consolidated net profit rises 82.88% in the September 2025 quarter



FINANCIAL DATA

In Cr.

Mar 2025Mar 2024Mar 2023
SOURCES OF FUNDS :   
Share Capital 12.7112.7112.65
Reserves Total 204.92196.49180.02
Equity Share Warrants0.000.000.00
Equity Application Money0.000.001.13
Read More
Mar 2025Mar 2024Mar 2023
INCOME :   
Sales Turnover 151.46172.39137.88
Excise Duty0.000.000.00
Net Sales151.46172.39137.88
Other Income 6.232.302.46
Read More
ParticularsDec 2025Sep 2025Jun 2025
Gross Sales 43.4942.2338.45
Excise Duty 000
Net Sales 43.4942.2338.45
Other Operating Income 000
Other Income  0.530.370.47
Read More
Category No. Of Shares Percentage (%)
Total Foreign 2413843 17.80
Total Institutions 59751 0.44
Total Govt Holding 7000 0.05
Total Non Promoter Corporate Holding 359323 2.65
Total Promoters 5487095 40.46
Total Public & others 5,235,803.00 38.61
Total 100.00 100.00
Read More
CORPORATE ACTIONS
Record Date Ex-Bonus Date Ratio
nodata
No Data Available!!!
Read More
Record Date Split Date Face Value Before Face Value After
nodata
No Data Available!!!
Read More
Read More
ANNOUNCEMENT DATE EX DIVIDEND DATE DIVIDEND (%) DIVIDEND TYPE
30-05-2025 19-09-2025 10 Final
29-05-2024 19-09-2024 10 Final
29-05-2023 20-09-2023 10 Final
25-05-2022 19-09-2022 10 Final
28-06-2021 16-09-2021 10 Final
PREMIUM (₹) RATIO RECORD DATE EX RIGHTS DATE
nodata
No Data Available!!!
Read More
Read More
FROM DATE EX TO DATE AGENDA
26-02-2026 NA Unaudited Financial Results fo...
13-02-2026 NA Medicamen Biotech Ltd-has info...
14-11-2025 NA Medicamen Biotech Ltd-has info...
26-09-2025 NA Outcome of the Board meeting h...
19-09-2025 26-09-2025 The Register of Members and ot...
COMPANY INFO

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence over 35+ countries. Its offerings include Finished Dosage Forms (FDF's) to African countries.

In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.

Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.

The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.

In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitmen

Read More
Get Free Demat Account
Captcha Image